Proqr Therapeutics N.V.2024财年第三财季实现净利润-8.91百万美元，同比减少43.48%

市场透视11-12

11月12日，Proqr Therapeutics N.V.（PRQR.US）公布财报，公告显示公司2024财年第三财季净利润为-8.91百万美元，同比减少43.48%；其中营业收入为4.22百万美元，同比增加183.22%，每股基本收益为-0.11美元。从资产负债表来看，Proqr Therapeutics N.V.（PRQR.US）总负债91.37百万美元，其中短期债务4.78百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482734549?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-12 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482734549","market":"us","top_or_hot":-1,"title":"Proqr Therapeutics N.V.2024财年第三财季实现净利润-8.91百万美元，同比减少43.48%","media":"市场透视","content":"<div>\n<p>11月12日，Proqr Therapeutics N.V.（PRQR.US）公布财报，公告显示公司2024财年第三财季净利润为-8.91百万美元，同比减少43.48%；其中营业收入为4.22百万美元，同比增加183.22%，每股基本收益为-0.11美元。从资产负债表来看，Proqr Therapeutics N.V.（PRQR.US）总负债91.37百万美元，其中短期债务4.78百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000040a22d0d7c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Proqr Therapeutics N.V.2024财年第三财季实现净利润-8.91百万美元，同比减少43.48%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProqr Therapeutics N.V.2024财年第三财季实现净利润-8.91百万美元，同比减少43.48%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000040a22d0d7c&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月12日，Proqr Therapeutics N.V.（PRQR.US）公布财报，公告显示公司2024财年第三财季净利润为-8.91百万美元，同比减少43.48%；其中营业收入为4.22百万美元，同比增加183.22%，每股基本收益为-0.11美元。从资产负债表来看，Proqr Therapeutics N.V.（PRQR.US）总负债91.37百万美元，其中短期债务4.78百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000040a22d0d7c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRQR","symbol_name":"ProQR Therapeutics N.V.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000040a22d0d7c&s=b","article_id":"2482734549","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000040a22d0d7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482734549","pubTimestamp":1731340831,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月12日，Proqr Therapeutics N.V.公布财报，公告显示公司2024财年第三财季净利润为-8.91百万美元，同比减少43.48%；其中营业收入为4.22百万美元，同比增加183.22%，每股基本收益为-0.11美元。从资产负债表来看，Proqr Therapeutics N.V.总负债91.37百万美元，其中短期债务4.78百万美元，资产负债比为0.02，流动比率为0.03。机构评级：截至2024年11月12日，当前有6家机构对Proqr Therapeutics N.V.目标价做出预测，其中目标均价为6.63美元，其中最低目标价为2.07美元，最高目标价为13.95美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PRQR":"ProQR Therapeutics N.V.","LENZ":"Therapeutics"},"translate_title":"Proqr Therapeutics N.V. achieved net profit of-US $8.91 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 43.48%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"PRQR":0.9},"content_text":"11月12日，Proqr Therapeutics N.V.（PRQR.US）公布财报，公告显示公司2024财年第三财季净利润为-8.91百万美元，同比减少43.48%；其中营业收入为4.22百万美元，同比增加183.22%，每股基本收益为-0.11美元。从资产负债表来看，Proqr Therapeutics N.V.（PRQR.US）总负债91.37百万美元，其中短期债务4.78百万美元，资产负债比为0.02，流动比率为0.03。机构评级：截至2024年11月12日，当前有6家机构对Proqr Therapeutics N.V.目标价做出预测，其中目标均价为6.63美元，其中最低目标价为2.07美元，最高目标价为13.95美元。公司简介：ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482734549"}